Search results
Results From The WOW.Com Content Network
Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.It consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein.
What: Shares of cancer-drug developer Dendreon (NAS: DNDN) were getting slammed today, losing 23% as investors reacted to the company's continued struggles to grow sales of its key prostate-cancer ...
So much for being less risky. Dendreon's (NAS: DNDN) stock is trading down 65% today on the heels of a disappointing quarter. Gone is the full-year revenue forecast of $350 million to $400 million ...
For premium support please call: 800-290-4726 more ways to reach us
A common stock dividend is the dividend paid to common stock owners from the profits of the company. Like other dividends, the payout is in the form of either cash or stock. The law may regulate the size of the common stock dividend particularly when the payout is a cash distribution tantamount to a liquidati
Key Points. Dividend King stocks with over a half century of dividend increases can often fall into a rut over time. Clues as to if a Dividend King stock is worth holding include such categories ...
The ex-dividend date (coinciding with the reinvestment date for shares held subject to a dividend reinvestment plan) is an investment term involving the timing of payment of dividends on stocks of corporations, income trusts, and other financial holdings, both publicly and privately held.
In this video, Motley Fool health-care bureau chief Brenton Flynn takes a closer look at Dendreon (NAS: DNDN) , a company that has underperformed recently, to shareholders' chagrin. Brenton looked ...